Dabomb Protein Biotech (ROCO:6578) Asset Turnover: 0.07 (As of Dec. 2025)


ROCO:6578 Dabomb Protein Biotech Corp ROCO:6578
59 GF Score
Price NT$16.50
GF Value NT$14.55
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Dabomb Protein Biotech Asset Turnover?

Dabomb Protein Biotech ROCO:6578 +0.30% 59 Asset Turnover is 0.07 as of Dec. 2025. GuruFocus rates ROCO:6578 with a GF Score™ of 59/100 and a GF Value™ of NT$14.55 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Dabomb Protein Biotech's Revenue for the three months ended in Dec. 2025 was NT$80.9 Mil. Dabomb Protein Biotech's Total Assets for the quarter that ended in Dec. 2025 was NT$1,143.2 Mil. Therefore, Dabomb Protein Biotech's Asset Turnover for the quarter that ended in Dec. 2025 was 0.07.

Asset Turnover is linked to ROE % through Du Pont Formula. Dabomb Protein Biotech's annualized ROE % for the quarter that ended in Dec. 2025 was -17.58%. It is also linked to ROA % through Du Pont Formula. Dabomb Protein Biotech's annualized ROA % for the quarter that ended in Dec. 2025 was -15.50%.


Dabomb Protein Biotech  (ROCO:6578) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Dabomb Protein Biotech's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-177.2/1007.9365
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-177.2 / 323.6)*(323.6 / 1143.1985)*(1143.1985/ 1007.9365)
=Net Margin %*Asset Turnover*Equity Multiplier
=-54.76 %*0.2831*1.1342
=ROA %*Equity Multiplier
=-15.50 %*1.1342
=-17.58 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Dabomb Protein Biotech's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-177.2/1143.1985
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-177.2 / 323.6)*(323.6 / 1143.1985)
=Net Margin %*Asset Turnover
=-54.76 %*0.2831
=-15.50 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Dabomb Protein Biotech Asset Turnover Related Terms


Dabomb Protein Biotech Asset Turnover Historical Data

* Premium members only.

The historical data trend for Dabomb Protein Biotech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dabomb Protein Biotech Asset Turnover Chart

Dabomb Protein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.33 0.29 0.25 0.26

Dabomb Protein Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.07 0.06 0.07

ROCO:6578 vs KHC, GIS: Asset Turnover Comparison

For the Packaged Foods subindustry, Dabomb Protein Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dabomb Protein Biotech Asset Turnover vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's Asset Turnover falls into.


ROCO:6578
59GF Score
Dabomb Protein Biotech Corp ROCO:6578
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dabomb Protein Biotech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Dabomb Protein Biotech's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=309.335/( (1315.271+1095.76)/ 2 )
=309.335/1205.5155
=0.26

Dabomb Protein Biotech's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=80.9/( (1190.637+1095.76)/ 2 )
=80.9/1143.1985
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.07 mean?
Dabomb Protein Biotech (ROCO:6578) has a Asset Turnover of 0.07 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Asset Turnover too high?
Dabomb Protein Biotech's current Asset Turnover is 0.07. Overall, Dabomb Protein Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Asset Turnover compare to KHC and GIS?
Dabomb Protein Biotech's Asset Turnover of 0.07 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Consumer Packaged Goods company?
A good Asset Turnover depends on the Consumer Packaged Goods industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Dabomb Protein Biotech and its competitors. Dabomb Protein Biotech's current Asset Turnover is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.55, compared to a current price of NT$16.50 — trading 13.4% above its estimated fair value. The current Asset Turnover is 0.07. Dabomb Protein Biotech's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Asset Turnover is 0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?

Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued. The current stock price of NT$16.50 is trading 13.4% above its estimated GF Value™ of NT$14.55. GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.

Key valuation signals for ROCO:6578:

  • Asset Turnover: 0.07
  • GF Value™: NT$14.55 vs. price of NT$16.50 (13.4% above fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dabomb Protein Biotech Business Description

Address No. 52, Industrial 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
59GF Score

Get the complete analysis for ROCO:6578

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.50
Price
NT$14.55
GF Value